Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
A Prospective, Randomized, Open-Label, 13 to 14-week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subjects With Left Ventricular Hypertrophy (LVH)
Sponsor: Allergan Sales, LLC
Listed as NCT03180593, this PHASE4 trial focuses on Blood Pressure and Hypertension Complicated and remains completed. Sponsored by Allergan Sales, LLC, it has been updated 6 times since 2017, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
May 2018 — Jun 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 1 earlier version
-
Jun 2017 — May 2018 [monthly]
Recruiting PHASE4
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan Sales, LLC
- Trinity Hypertension & Metabolic Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Carrollton, United States